40 employees
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
2018
$69M
from 2 investors over 2 rounds
Neurogene Inc. raised $69M on February 12, 2019
Investors: Samsara BioCapital and Redmile Group